Ramanan Laxminarayan

Chair

Ramanan Laxminarayan is founder and director of the Center for Disease Dynamics, Economics & Policy (CDDEP) in Washington, D.C., and a senior research scholar and lecturer at the Princeton Environmental Institute at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Kwazulu Natal. Laxminarayan is founder of HealthCube, which works to improve access to healthcare and diagnostics worldwide. Since 1995, Laxminarayan has worked to improve the understanding of antibiotic resistance as a problem of managing a shared global resource. His work encompasses extensive peer-reviewed research, public outreach, and direct engagement in eleven countries in Asia and Africa through the Global Antibiotic Resistance Partnership. Through his prolific research, active public outreach (including a widely viewed TED talk) and sustained policy engagement, he has played a central role in bringing the issue of drug resistance to the attention of leaders and policymakers worldwide and to the United Nations General Assembly in September 2016. Laxminarayan has served on the U.S. President’s Council of Advisors on Science and Technology’s antimicrobial resistance working group and is currently a voting member of the U.S. Presidential Advisory Council on Combating Antimicrobial Resistance. He is a series editor of the Disease Control Priorities for Developing Countries, 3rd edition. In 2003-04, he served on the National Academy of Science/Institute of Medicine Committee on the Economics of Antimalarial Drugs and subsequently helped create the Affordable Medicines Facility for malaria, a novel financing mechanism for antimalarials. In 2012, Laxminarayan created the Immunization Technical Support Unit that supports the immunization program of the Ministry of Health and Family Welfare of the Government of India and which is credited with helping rapidly improve vaccination coverage and introduction of four new vaccines. As Vice President, Research and Policy at the Public Health Foundation of India between 2011 and 2015, he led the growth of a research division to over 700 technical and research staff. Laxminarayan’s work has been covered in major media outlets including Associated Press, BBC, CNN, the Economist, LA Times, NBC, NPR, Reuters, Science, Wall Street Journal, and National Journal.

John-Arne Røttingen

Vice-Chair

John-Arne Røttingen is Ambassador for Global Health at the Ministry of Foreign Affairs, Norway. He is Adjunct Scientific Director at the Norwegian Institute of Public Health and Visiting Fellow of Practice at Blavatnik School of Government, Oxford University. He was the founding CEO of CEPI – Coalition for Epidemic Preparedness Innovations; and has been the Chief Executive of the Research Council of Norway; Executive Director of Infection Control and Environmental Health at the Norwegian Institute of Public Health; founding Chief Executive of the Norwegian Knowledge Centre for the Health Services; Professor of Health Policy at the Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo; and Adjunct Professor at the Department of Global Health and Population, Harvard T.H. Chan School of Public Health. He is member of the Norwegian Academy of Science and Letters and the US National Academy of Medicine. He received his MD and PhD from the University of Oslo, an MSc from Oxford University and an MPA from Harvard University.

Stanislas
Zuin

Board Treasurer

Stanislas ZUIN is a certified internal auditor (CIA) and a certified fraud examiner (CFE). He holds master degrees in both economics and economic crime investigation, as well as a certificate in development studies. Throughout his career he has worked as a private banking financial analyst, a corporate finance executive, and CFO for both privately-owned and listed industrial companies. He later founded his own consulting firm in economic crime investigation, before being elected from 2006 to 2018 as magistrate at the Court of auditors of Geneva, Switzerland. As magistrate he has managed numerous compliance and performance audits as well as fraud investigations and evaluation of public policies. He has served four years as the President of the Court and is a frequent lecturer at Universities in the fields of public finance, investigation and audit. He currently leads its own consultancy company in the field of audit and governance, together with responsibilities as Board Vice President of Geneva International Airport, in charge of Audit & Finance committee, and as Board Member of the Geneva federation for cooperation and development (FGC).

Glenda
Gray

Board member

Professor Glenda Gray is the President of the Medical Research Council in South Africa, a non-Executive Director at the Perinatal HIV Research Unit (PHRU), in Soweto, South Africa, and a Professor of Paediatrics in the Faculty of Health Sciences at the University of the Witwatersrand. Her prior research has focused on: prevention of mother to child transmission studies, paediatric treatment trials, large scale HIV clinical trials (including HIV vaccine trials); TB, influenza and HPV vaccine studies in infants, children, adolescents and adults. She has been the recipient of multiple grants from the NIH, including an R21 and a U01. In 2009, she received the N’Galy Mann Lectureship award at The Conference on Retroviruses and Opportunistic Infections (CROI). Professor Gray has been the Soweto Clinical Trials Unit PI since 2010. In addition, she is the HVTN Co-PI, and Director of International/Africa Programs. Prof. Gray has been involved in HIV research in South Africa for more than a decade. She is currently leading the clinical development of South Africa’s first two HIV vaccines. She has expertise in HIV prevention in adolescents, and is the co-chair for a pivotal study investigating the efficacy of coitally dependent tenofovir gel, called FACTS 001. This multi-centered study involves multiple clinical trial sites, and is a purely South African run consortium, giving Prof. Gray the necessary experience and expertise in leading multi-centered studies. Prof. Gray serves on the WHO/UNAIDS Vaccine Advisory Board, and on the DSMB for two vaccine studies in Africa. She chairs the standing committee on health, for the Academy of Science, and represent the academy in the South African National Research Committee. As a recently inducted member of the Institute of Medicine of the National Academies, US, she served on the Global Health Committee, and the Vaccine Committee.

Veronika von Messling

Board member

Prof. Dr. Veronika von Messling, is Director-General for Life Sciences at the German Federal Ministry of Education and Research. She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany. After postdoctoral training at Mayo Clinic in Rochester, MN, she was Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore, before becoming Director of the Veterinary Division at Paul-Ehrlich-Institute, the German Federal Institute of Vaccines and Biomedicines, in Langen, Germany.

Hiroki
Nakatani

Board member

In recent years, Dr. Hiroki Nakatani has held academic positions in Japan as Project Professor at the Global Research Institute of Keio University, and Invited Professor at Osaka University Post Graduate School of Medicine. He also serves in various national and international organizations as Chair, Board of Directors, Global Health Innovative Technology Fund (GHIT Fund); Senior-Advisor, Economic Research Institute for ASEAN and East Asia (ERIA; Director, Hub on Population Ageing, Association of Pacific Rim Universities (APRU); Member, Board of Directors, National Center for Global Health and Medicine; and Director, Human Resource Strategy Center for Global Health. He is a veteran public health specialist for over 40 years, who started his career at the Ministry of Health, Labour and Welfare in Japan. He worked extensively in the area of health policy, public health, international health, and health science and technology. His national career includes serving as Director-General of Health and Welfare Services in Hiroshima Prefecture, where he was in charge of integration of health and welfare services in preparation for the arrival of a rapidly ageing society. With regards to international career, he served the WHO Headquarters twice. From April 1988 to March 1993, he was Policy Analysist in the Department of Human Resource for Health. From March 2007 to May 2015, he served as Assistant Director-General of WHO, leading the largest technical cluster of HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases. During his tenure, the morbidity and mortality of these three major infections showed trends of decline, and a few tropical diseases were on track towards elimination and even eradication (dracunculiasis or guinea worm disease). Dr. Nakatani received his MD from Keio University School of Medicine, MHPEd from the University of New South Wales, and PhD from Keio University.

Bernard
Pécoul

Board member

Dr Bernard Pécoul has led the Drugs for Neglected Diseases initiative (DNDi) since its foundation in 2003. Under his guidance, DNDi – a not-for-profit research and development organization – with hundreds of public and private partners, has delivered seven new treatments for the most neglected diseases (leishmaniasis, sleeping sickness, and Chagas disease) and for malaria. It has developed a robust portfolio of projects spanning from discovery to implementation for these diseases as well as filaria, paediatric HIV, mycetoma, and hepatits C. As part of DNDi’s dynamic portfolio approach, Dr Pécoul is also leading the incubation of a product development partnership to address R&D for new antibiotic treatments. DNDi aims to deliver a total of 16 to 18 new treatments for neglected patients by 2023, with a total of EUR 650 million, spanning 10 disease areas. The initiative, through its R&D work, also builds capacity in disease endemic countries through research platforms and technology transfers and advocates for greater public leadership to sustainably address the health needs of neglected patients. Prior to DNDi, Dr Pécoul was Director of the Médecins Sans Frontières (MSF) Campaign for Access to Essential Medicines from 1998 to 2003, a position he took on after that of Executive Director of MSF-France. While working with MSF, Dr Pécoul carried out field missions in Africa, Latin America, and Asia. In 1988, he co-founded Epicentre, an MSF-affiliated NGO specialized in epidemiology. After obtaining his medical degree at the University of Clermont-Ferrand, France, Dr Pécoul earned a master’s degree in public health at Tulane University, USA. In 2012, he was awarded an honorary Doctor of Laws Degree by the University of Dundee, UK. Bernard Pécoul is member of the Joint Coordination Board of the Special Programme for Tropical Disease Research (WHO/TDR) and a former board member of UNITAID’s Medicines Patent Pool.

Gregg
Alton

Board observer

Mr. Alton spent more than 20 years at Gilead Sciences, where he served in an array of leadership roles across a portfolio of responsibilities. From January 2019 until March 2019, Mr. Alton was Gilead’s interim chief executive officer. Prior to that, he was the company’s chief patient officer, responsible for Gilead’s government affairs, public affairs, patient outreach, and engagement initiatives, as well as efforts to facilitate access to its medicines around the world. During his tenure at Gilead, his wide-ranging roles included leadership of commercial operations in Europe, Asia, Latin America, and Africa, as well as global medical affairs. He also served as general counsel and chief compliance officer. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in corporate finance transactions for healthcare and information technology companies. Mr. Alton currently serves on the United States Presidential Advisory Council on HIV/AIDS, is a member of the board of directors of Novavax Inc., Brii Biosciences, Corcept Therapeutics, Enochian Biosciences, and several non-profit organizations, including The Hepatitis Fund, ETR and the Boys and Girls Clubs of Oakland. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.

Hanan H.
Balkhy

Board observer

Assistant Director-General, Antimicrobial Resistance, World Health Organization Professor Hanan H. Balkhy is the first appointed Assistant Director-General for the Antimicrobial Resistance Division (AMR) at the World Health Organization (WHO), which is a flagship program and has the mandate to lead the human health response to the emergence of antimicrobial resistance along with the relevant stakeholders. Dr Balkhy is a Professor of Pediatric Infection Diseases with over two decades of experience in the field of infectious diseases and Infection Prevention and Control (IPC), a clinician and a researcher with over 150 publications. Prior to her appointment she was the Executive Director, Infection Prevention and Control, at the Ministry of National Guard (MNG) and the Director of the Gulf Cooperation Council Centre for Infection Control. She led the WHO Collaborating Centre for IPC and AMR in Saudi Arabia between 2009-2019. Dr Balkhy is also the first appointed chair for the Infectious Disease Research Unit at King Abdullah International Medical Research Center at King Saud bin Abdulaziz University for Health Sciences in Riyadh, Saudi Arabia. In this role, she developed and led a team of scientists with a focus on relevant infectious disease research, such as multidrug resistance pathogens and hospital acquired infections, as well as research on regional public health concerns including MERS- CoV, Salmonella and Brucellosis. She was the Editor-in-Chief of the Journal of Infection and Public Health from 2009-2019. Dr Balkhy is a graduate of King Abdulaziz University in Jeddah, Saudi Arabia. She completed her pediatric residency at Massachusetts General Hospital in Boston, USA, from 1993-1996, followed by a pediatric infectious diseases fellowship from 1996-1999 at Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, Ohio, USA. Dr Balkhy has served as an expert on many WHO committees including: the Review Committee on the Role of the International Health Regulations (2005) in the Ebola Outbreak and Response, the Advisory Group on Integrated Surveillance and Antimicrobial Resistance (AGISAR), the Strategic and Technical Advisory Group on Antimicrobial Resistance (STAG-AMR), and the International Health Regulations Review Committee (IHR-RC).

Prabhavathi Fernandes

Board observer

Prabhavathi Fernandes, PhD., FIDSA Dr. Prabhavathi Fernandes, Ph.D., has more than 35 years of pharmaceutical discovery, development and management experience having held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. During these years she was directly involved in the development of six antibiotics, including aztreonam, fidaxomicin, and clarithromycin. After leaving Bristol- Myers Squibb, she has founded and led four biotechnology and CRO companies as President, Chief Executive Officer and Director of each of these companies, including Cempra, Inc., DarPharma, Ricerca and Small Molecule Therapeutics. Dr. Fernandes is the Chairperson of the National Biodefense Science Board (NBSB) for the United States government. She also serves as the Chair of the New Antibiotic Pipeline working group for the World Health Organization and is a member of the NIH ACTIV working group for COVID. She is a Director of the Boards of Ocugen, OpGen and Aelin Therapeutics and an Advisor to Felix Biotechnology. She has authored over 250 publications and several reviews, book chapters and served as an editor for books and is the section editor for the Journal of Antibiotics. Dr. Fernandes obtained her undergraduate and Master’s degree training in India, worked at the University of Ghent, Belgium in Immunochemistry, received her Ph.D. in Microbiology from Thomas Jefferson University, Philadelphia. She has been granted her FIDSA by the Infectious Diseases Society of America.

Ambassador Nora Kronig Romero

Board observer

Ambassador for Global Health Nora Kronig Romero is Vice-Director General of the Federal Office of Public Health and heads the International Affairs Division.As a diplomat, she worked in the Federal Department of Foreign Affairs (FDFA) for more than 10 years. Her last position was Deputy Head of the Multilateral division at the Permanent Mission of Switzerland to the United Nations Office at Geneva. Before that, she worked as Chief of Staff of the State Secretary for Foreign Affairs Yves Rossier (2012-2016) and as diplomatic assistant of the State Secretary Peter Maurer (2010-2012), among other positions. She holds a degree in economics from the University of St. Gallen.

Prabhavathi Fernandes

Chair

Prabhavathi Fernandes, PhD., FIDSA Dr. Prabhavathi Fernandes, Ph.D., has more than 35 years of pharmaceutical discovery, development and management experience having held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. During these years she was directly involved in the development of six antibiotics, including aztreonam, fidaxomicin, and clarithromycin. After leaving Bristol- Myers Squibb, she has founded and led four biotechnology and CRO companies as President, Chief Executive Officer and Director of each of these companies, including Cempra, Inc., DarPharma, Ricerca and Small Molecule Therapeutics. Dr. Fernandes is the Chairperson of the National Biodefense Science Board (NBSB) for the United States government. She also serves as the Chair of the New Antibiotic Pipeline working group for the World Health Organization and is a member of the NIH ACTIV working group for COVID. She is a Director of the Boards of Ocugen, OpGen and Aelin Therapeutics and an Advisor to Felix Biotechnology. She has authored over 250 publications and several reviews, book chapters and served as an editor for books and is the section editor for the Journal of Antibiotics. Dr. Fernandes obtained her undergraduate and Master’s degree training in India, worked at the University of Ghent, Belgium in Immunochemistry, received her Ph.D. in Microbiology from Thomas Jefferson University, Philadelphia. She has been granted her FIDSA by the Infectious Diseases Society of America.

Karl-Heinz
Altmann

Committee member

Karl-Heinz Altmann has been a Professor of Pharmaceutical Sciences at the Swiss Federal Institute of Technology (ETH) in Zürich since July 2003. Professor Altmann studied chemistry at the University of Mainz, Germany and he holds a PhD degree in organic chemistry from the University of Basel, Switzerland. From 1990 to 1996 he was a research scientist and group leader at Ciba-Geigy Central Research in Basel. In 1997 he moved to Oncology Research of Novartis Pharma, until in 2000 he was appointed the Novartis Senior Chemistry Expert. From January to July 2003 he was the acting Global Head of Chemistry of the Novartis Institutes for BioMedical Research. Research in the Altmann group is centered on the chemical synthesis of pharmaceutically relevant natural products/ natural product analogs and their biological evaluation, with a particular focus on leads for anticancer and antituberculosis drug discovery. In 2014 Professor Altmann was awarded the Paul Ehrlich Prize of the Société de Chimie Thérapeutique, France.

Marc
Bonten

Committee member

Dr. Marc Bonten is Professor of molecular epidemiology of infectious diseases at University Medical Centre Utrecht in Utrecht, The Netherlands. He obtained his PhD (“the role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia, 1994) at the Maastricht University, the Netherlands. He started his career as a registered internist in 2000, specialized in infectious disease since 2002 and became a clinical microbiologist in 2008 for the University Medical Center Utrecht, the Netherlands. From 2008 till 2021 he was head of the department Medical Microbiology and since 2003 he is leading the research group of infectious Disease Epidemiology at the Julius Center of Health Sciences and Primary Care, both at the UMC Utrecht, where he also is chairman for the Infection & Immunity Focus Program. In 2021 he was elected member of the Dutch National Academy of Sciences. He received the VICI laureate in 2006 from the Dutch Science Association, was PI of the CAPiTA study (investigator-initiated study funded by Wyeth, later Pfizer), and coordinator of the IMI-funded consortiums COMBACTE-NET, COMBACTE-CARE, COMBACTE-MAGNET and COMBACTE-CDI. For his research efforts he was awarded with the Excellence Award of the European Society of Clinical Microbiology and Infectious Diseases in May 2015.

Anthony
Coates

Committee member

Anthony Coates is the Professor of Medical Microbiology at St George’s, University of London. His main research interests are in antibiotic development and in tuberculosis. For 30 years he worked with Professor Dennis Mitchison, the world expert in combination chemotherapy of tuberculosis.  With Dr Yanmin Hu, Dr Coates invented a new platform technology to create novel patented combinations of repurposed or new antimicrobials which can rescue existing antibiotics. He founded the Antibiotic Biotech, Helperby Therapeutics plc, to develop new combinations, one of which is in the market, one has completed Phase II, two are in Phase II, and two are in late stage preclinical development. These combinations are potential new treatments for highly resistant bacterial infections including complicated urinary tract infections, Cystic Fibrosis, complicated skin infections, and disinfection. He has been awarded numerous national and international grants from the European Commission, British MRC, charities and industry, and named inventor on over 128 patents with co-inventor Dr Yanmin Hu. He has published more than 180 peer-reviewed publications and 13 books as editor (ORCID: https://orcid.org/0000-0001-8052-3175), He serves on the Scientific Advisory committee of the Global Antibiotic Research and Development Partnership(GARDP) and serves as a director on the board of Biotechs from Europe innovating in Anti-Microbial resistance Alliance (BEAM). He founded the networks Antibiotic Discovery-UK, Antibiotic Discovery-Global, and co-founded BEAM and the world’s first antibiotic discovery charity called Antibiotic Research-UK.

Ana Cristina Gales

Committee member

Ana Cristina Gales is Professor at the Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM-UNIFESP), and Director of the Laboratory Alerta at the same institution. She received her medical degree from the Faculdade de Medicina FUABC (1991), and continued her residency training in Internal Medicine and Infectious Diseases (1992-1995) at the EPM-UNIFESP, São Paulo, Brazil. She finished her PhD in Health Sciences at EPM-UNIFESP (2001) after completing her research fellowship in Medical Microbiology at the Department of Pathology, University of Iowa, Iowa City, USA (1998-2000). Dr. Gales’ research has been focused on the molecular epidemiology of multidrug-resistant bacteria and in vitro activity of new antimicrobials. She has authored more than 240 publications in peer-reviewed journals, accumulating more than 9,900 citations (H index 50) up to August, 2021, according to data provided by Scopus. Dr. Gales is a full member of the Technical Chamber on Microbial Resistance in Health Services (CATREM), with the purpose of advising the Brazilian Health Surveillance Agency (ANVISA) in establishing standards and measures for monitoring, control, and prevention of antimicrobial resistance in Brazilian health services. She has also collaborated with several worldwide programs to monitor antimicrobial resistance rates and phenotypes among clinically relevant pathogens and served as Chair of the Brazilian Committee on Antimicrobial Susceptibility (BrCAST, 2017-2018). She is also an associate editor for mSphere®, The Brazilian Journal of Infectious Diseases, and the Journal of Global Antimicrobial Resistance.

Angela Dramowski

Committee member

Angela Dramowski is an Associate Professor of Paediatric Infectious Diseases at Tygerberg Hospital/Stellenbosch University, Cape Town, South Africa. She has a passion for infection prevention and antimicrobial stewardship, with a research focus on the treatment and prevention of infections in hospitalised neonates and children in low-resource settings.

Roy Jamieson

Committee member

Roy is a Pharmacist by training graduating from Nottingham University, UK and now based in Sweden. During his early formative career, he gained experience in pharmaceutical development and manufacturing. He is an experienced Pharma Industry & Regulatory CMC professional having spent time as a quality assessor at MHRA and with over 25 years in large pharma organisations leading numerous small molecule projects from FTiH through Marketing Authorisation and launch. As an Independent Consultant he has worked with many small companies as well as collaborating with consultancy firms & a UK based pharmaceutical development service company.  He is currently supporting the South African Agency (SAHPRA) as a Quality/CMC reviewer supporting their generic backlog programme and has recently started supporting a Swedish based rare disease Biotech company with their biologics portfolio. Roy has successfully led 4 major global submissions through Phase 3 to marketing authorisation approval. His key area of regulatory scientific expertise and interest centres on biopharmaceutics aspects of solid oral dosage forms of small molecules and the bridge between quality performance and the pharmacokinetic profile linked to safety and efficacy.

Mark J Goldberger

Committee member

Dr Goldberger received his MD degree from the Columbia University College of Physicians and Surgeons in New York and his MPH from George Washington University in Washington, DC. He completed his postgraduate training at the Presbyterian Hospital in New York and the Centers for Disease Control (CDC) in Atlanta. He is board certified in internal medicine and infectious disease and is a fellow of the Infectious Diseases Society of America. Dr Goldberger was on the faculty of Columbia University for nine years. He joined the Food and Drug Administration in 1989. At the FDA he served as primary reviewer, medical team leader, Director of the Division of Special Pathogen and Immunologic Drug Products and Director of the Office of Antimicrobial Products within the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA). In addition to these positions he coordinated drug shortage activities within the CDER from 1990 -­ 2006. Dr Goldberger also was the FDA lead in an assessment of the readiness of the Pharmaceutical Industry for Y2K. In 2000 he spent 8 months as acting Associate Center Director for Quality Assurance in CDER during which time he developed the concept of the Regulatory Briefing. In 2003-­2004 he was Acting Deputy Center Director of CDER. In 2006 he became Medical Director for Emerging and Pandemic Threat Preparedness within the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration. In October 2007 he joined Abbott as Divisional Vice President – Regulatory Policy and Intelligence. In this role he was involved in multiple areas of both product and policy development. He continued in this position when AbbVie separated from Abbott until May 2013 when he became VP Regulatory Affairs and Senior Advisor. In this position he provided regulatory and scientific input both into multiple development programs and in the preparation of marketing applications. In September 2014 he retired from AbbVie and opened his own consulting practice as Mark Goldberger MD MPH LLC.

William Hope

Committee member

Prof William Hope FRACP, FRCPA, PhD - Dame Sally Davies Chair of AMR Research, Director of Centre of Excellence in Infectious Diseases Research William Hope (BMBS, FRACP, FRCPA, PhD), is Dame Sally Davies Chair of AMR Research at the University of Liverpool in the UK. Professor Hope is a Fellow of the Royal Australasian College of Physicians and a Fellow of the Royal College of Pathologists of Australasia. Professor Hope qualified in Medicine in 1991, before undertaking specialist training in infectious diseases and clinical microbiology.  He completed his PhD in antimicrobial pharmacology in 2006, while undertaking fellowships at the University of Manchester, UK, and the National Institutes of Health, Bethesda, USA.  He was an NIHR Clinician Scientist and this award focussed on individualised antimicrobial therapy. Professor Hope leads the Centre of Excellence in Infectious Diseases Research (CEIDR) which focuses on antimicrobial resistance. Areas of special interest and research are antimicrobial pharmacokinetics and pharmacodynamics, antimicrobial drug development and individualisation of antimicrobial therapy. He is a Fellow of the American Academy of Microbiology and European Society of Clinical Microbiology and Infectious Diseases.

Marc Mendelson

Committee member

Dr Marc Mendelson is Professor of Infectious Diseases and Head of the Division of Infectious Diseases & HIV Medicine at Groote Schuur Hospital, University of Cape Town (UCT). He studied Medicine at St Mary’s Hospital, London and specialized in Infectious Diseases at Addenbrookes Hospital, Cambridge, where he attained his PhD. He moved to The Rockefeller University, New York in 2001 and subsequently to UCT to work on tuberculosis and innate immunity. Marc is Chair of the Ministerial Advisory Committee on Antimicrobial Resistance, the South African lead for Antimicrobial Resistance on the Global Health Security Agenda, co-chair of the South African Antibiotic Stewardship Programme, and co-author the South African Antimicrobial Strategic Framework. He is the past-President of both the Federation of Infectious Diseases Societies of Southern Africa and the International Society for Infectious Diseases. His focus is on national and international policy around access, appropriate use and innovation to combat antimicrobial resistance.

Rudo Mathivha

Committee member

MB.ChB, FCPaed(SA) –Critical Care, DBS (BM); PGDHSE(Wits) Professor L.R. Mathivha graduated Critical Care Medicine from the University of Natal (South Africa). She completed a Pediatric Residency at Chris Hani Baragwanath Academic Hospital before embarking on an Educational sojourn at Duke University Medical Center, Durham, North Carolina, USA. At Duke University, she completed a fellowship in pediatric critical care. Her current designation is Director of Critical Care Medicine at Chris Hani Baragwanath Academic Hospital where she runs a combined Adult and Paediatric Critical Care Fellowship Programme. She is the Immediate Past Vice President of the Society of Critical Care of Southern Africa; past Chairperson of the South African Medical Association’s Committee of Education, Science and Technology; past member of the Ministerial Committees of Health Technology Management and Revitalization of Emergency Medical Services; and Former Chair and Vice Chairperson of the Hospital’s Medical Advisory Committee. Her interests are diverse, including: non-conventional modes of respiratory support of the critically ill; antimicrobial stewardship, pharmacokinetics and pharmacodynamics of antimicrobials in septic critically ill patients; ICU utilization in resource constrained environments; and pediatric HIV in ICU and cardiovascular support in PICU.

Malcolm Page

Committee member

Dr Malcolm Page, PhD, studied Biochemistry in the U.K. and worked at the EMBL Heidelberg and the Biozentrum, Basel. He joined Roche in 1990, working on the discovery of β-lactamase inhibitors and anti-MRSA cephalosporins. He subsequently became responsible for exploratory projects in the Infectious Diseases therapeutic area and worked on the validation and screening of novel targets for antibiotics. Later, he led the Discovery Technologies group at Roche. In 2000 he joined Basilea Pharmaceutica as Head of Biology and has continued to work on the discovery of new antibiotics. Malcolm Page is author of over eighty original research articles, numerous posters as well as patents, reviews and book chapters. He is a “Privatdozent” for Biochemistry at the University of Basel and a visiting lecturer at the Department of Organic Chemistry of Bern University.  In 2002, he was appointed honorary Professor in Biological Sciences at Birmingham University. Since retiring in 2015, he continues to work as a consultant in antimicrobial drug discovery, including with the Innovative Medicines Initiative “New Drugs for Bad Bugs” and is affiliated with the Jacobs University in Bremen, where he is Wisdom Professor of Medicinal Chemistry and Chemical Biology.

Andreas Rummelt

Committee member

Dr. Andreas Rummelt is Chairman and Managing Partner of InterPharmaLink AG, a Management Consulting firm in Basel, Switzerland. His international career in pharmaceuticals has focused on the areas of technical research & development, manufacturing, and quality as well as on running a generics business as CEO. He has served more than twenty years in executive management positions in the industry. Dr. Rummelt was formerly Group Head of Quality Assurance and Technical Operations at Novartis, a position he held from 2008 until 2010. He had been a member of the Executive Committee of Novartis from 2006 until his resignation in 2010. He joined Sandoz Pharma Ltd. in 1985 in Switzerland and held various positions of increasing responsibility in Development. In 1994 he was appointed Head of Worldwide Technical Research and Development, a position he retained following the merger with Ciba-Geigy that created Novartis in 1996. From 1999 to 2004, A. Rummelt served as Global Head of Technical Operations of the Novartis Pharmaceuticals Division in Basel, Switzerland, and from 2004 to 2008, as Global CEO of Sandoz, the Generics Division of Novartis, in Vienna, Austria and Holzkirchen, Germany. Andreas Rummelt is a member of the Boards of Directors of AstraZeneca, UK (LSE, STO, Nasdaq) and of the privately held companies Alvogen Lux Holdings S.à r.l., L, Cypralis Ltd, UK, Leukocare AG, DE, Polyplus-transfection SA, F and Xellia Pharmaceuticals ApS, DK. A. Rummelt is pharmacist and earned his Ph.D. in Pharmaceutical Sciences from the University of Erlangen-Nuremberg, Germany, in 1983. He received his executive training in general management and leadership from the IMD in Lausanne, INSEAD in Fontainebleau, and Harvard Business School in Cambridge, USA.

Kamini Walia

Committee member

Kamini Walia, PhD MPH, is a microbiologist by training and has subsequently trained in public health from Johns Hopkins. She is working as Senior Scientist in the Division of Epidemiology and Communicable Diseases Division of Indian Council of Medical Research. She spent 2 years in PATH, as Director, Research and Development. During her 20 years of experience in public health space, she has initiated and successfully steered numerous projects and programs of public health importance in the field of infectious diseases, reproductive and child health and noncommunicable diseases. Dr Walia is currently leading the Antimicrobial Resistance Initiative of ICMR which focusing at various aspects of AMR, including surveillance, antimicrobial stewardship and OneHealth aspects . She curated the National Essential Diagnostics for the country to improve availability of diagnostics at all levels of health care. She is former member WHO Scientific Advisory Group of Experts on Essential Diagnostics and Commissioner on Lancet Commission on Diagnostics. Dr Walia’s experience spans working on infectious diseases, including HIV/AIDS programs and heath technologies including vaccines and diagnostics. She, through her initiatives, has always supported collaborations with other public health partners in public health space. She is recipient if ICMR’s Shakuntala Amir Chand award and Indian National Science academy, Young Scientist Award. She has received numerous fellowships and trainings from WHO, NIH, USA, IVI, Seoul, Pasteur Institute, France.

Nicholas White

Ex-officio member

Nicholas John White is Professor of Tropical Medicine at the Faculty of Tropical Medicine, Mahidol University, Thailand and at Oxford University, UK. He is also a consultant Physician at the John Radcliffe Hospital, Oxford and chairs the DNDi Scientific Advisory Committee. Professor Nick White is also a Wellcome Trust Principal Research Fellow who chairs the Wellcome Trust Tropical Medicine Research Programmes in South East Asia. He has lived and worked in Thailand since 1980. His research focus is the pathophysiology and treatment of malaria. He has concentrated on characterizing antimalarial pharmacokinetic-pharmacodynamic relationships to improve the treatment of malaria and reduce the emergence of resistance. This led to artemisinin based combination treatment for falciparum malaria, and the change to artesunate for severe malaria. He has authored over 900 scientific publications and 40 book chapters. He currently chairs the WorldWide Antimalarial Resistance Network and he co-chairs the WHO GMP technical expert group on prevention and treatment of malaria, and the WHO antimalarial treatment guidelines committee.

Dr. Valeria Gigante

Ex-officio member

Dr. Valeria Gigante is a Clinical Pharmacologist and a senior Regulatory Affairs and Health Policy specialist with thirteen years’ experience in public health. She is Team Lead at the World Health Organization (WHO) in the AMR Division where she coordinates research and priority-setting. Dr Gigante started her career in Regulatory Affairs in London at the European Medicines Agency (EMA) in 2007 where she worked as Scientific Administrator on safety and efficacy of medicines for human use. She joined the Italian Medicines Agency (AIFA) in 2010 as Clinical Assessor (PK/PD) for EU centralized procedure. She joined the WHO in 2017 where she coordinated the development of WHO guidelines on pharmaceutical regulation. Dr Gigante holds a Master Degree in Pharmacy with training in Microbiology and Hygiene and a Ph.D. in Pharmacology and Toxicology on available therapies for MDR-TB. She has published with the EMA MSWG on advanced methods for dose and regimen finding during development, on MID3 good practices, on scaling dose exposure response and with WHO on Bioequivalence/Biowaiver. She is currently writing and contributing to several WHO guidelines, policy documents and publications. She contributes as peer reviewer to the WHO Bulletin. Dr Gigante has served as an expert on international experts groups such as the EMA Modeling and Simulation Working Group (MSWG) and the Council of Europe Working Party on Pharmaceuticals and medical devices for the the revision of the Regulation N. 726/2004/EC. She represents WHO at the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Ambassador Nora Kronig Romero

Chair

Ambassador for Global Health Nora Kronig Romero is Vice-Director General of the Federal Office of Public Health and heads the International Affairs Division.As a diplomat, she worked in the Federal Department of Foreign Affairs (FDFA) for more than 10 years. Her last position was Deputy Head of the Multilateral division at the Permanent Mission of Switzerland to the United Nations Office at Geneva. Before that, she worked as Chief of Staff of the State Secretary for Foreign Affairs Yves Rossier (2012-2016) and as diplomatic assistant of the State Secretary Peter Maurer (2010-2012), among other positions. She holds a degree in economics from the University of St. Gallen.

Jasper
Claessen

Committee member

Jasper Claessen (PhD) is a Senior Advisor at the Department of Pharmaceutical affairs, at the Dutch Ministry of Health. He works on policies regarding the development of innovative medicines, with a special interest in the synergy between public and private interests in medicine development. He coordinates the Dutch policies aimed to stimulate R&D into novel antimicrobials, and represents the Dutch Ministry of Health in several national and international organizations that aim to tackle the AMR crisis. Furthermore, he is involved in the Dutch crisis response team aimed at making new COVID-19 medication accessible, and coordinates a comprehensive study into the financial ecosystem surrounding novel drug development. Prior to joining the ministry, he worked for several years as an innovation consultant building public/private R&D partnerships, and attracting funding for drug development programs and other health innovation initiatives. Trained as a molecular biologist, Jasper Claessen spend many years as an academic researcher at MIT and Cambridge University.

Dr Eiji
Hinoshita

Committee member

Dr Eiji Hinoshita is an Assistant Minister for Global Health and Welfare, Japanese Ministry of Health, Labour and Welfare (MHLW). He started his professional career as a surgeon in Fukuoka, Japan. After post-graduate study of biochemistry, Dr Hinoshita joined in MHLW in 2001, where he acquired a wide range of technical experiences in public health, including disease control and prevention, regulatory science and so on. He has previously worked for Japanese Ministry of Foreign Affairs (MOFA), where he committed to global health including the governance of Global Health Innovative Technology (GHIT) Fund, which was a Japan-based international public-private partnership fund for global health R&D. Before taking the current position, he served as Director-General, Bureau of International Health Cooperation, National Center for Global Health and Medicine (NCGM), where he also committed to global health including the establishment of R&D platform between Japan and ASEAN countries.

Louise Norton-Smith

Committee member

Louise Norton-Smith is Head of Global Antimicrobial Resistance (AMR) Strategy at the UK Department of Health and Social Care, as well as the G7 2021 Workstream Lead for AMR. She oversees a broad range of globally-facing AMR priorities, including the Global AMR Innovation Fund (GAMRIF), the UK government’s diplomatic priorities on AMR and the office of the UK Envoy on AMR, Dame Sally Davies. Prior to joining the Civil Service in 2011, Louise was based in Paris and worked with Internews Europe, an international NGO specialising in media development and access to high-quality information. She has also worked in Sudan and Uganda in humanitarian response and sexual and reproductive health projects. Louise has master’s degrees in social anthropology and geography from the University of Edinburgh, Scotland and in international development from the University of Paris (Panthéon-Sorbonne), France where she was an Entente Cordiale scholar.

Dagmar Reitenbach

Committee member

Since 2007, Ms Reitenbach is the Head of the Global Health Team in the German Ministry of Health. After law studies at the University of Bonn with a special focus on labour law and social security law, she started her professional career as a speech writer in the Federal Ministry for Labour and Social Affairs. She then worked in the press office at the Federal Ministry for Labour and Social Affairs. Subsequently, she became the Head of the press office at the Federal Ministry for Labour and Social Affairs, the Federal Ministry for Health and Social Security and the Federal Ministry of Health.

Niresh Bhagwandin

Committee member

Niresh Bhagwandin has an MSc in laser physics from the University of Natal and PhD in Biomedical Engineering from the University of Cape Town. In his doctoral studies, he investigated the laser-induced fluorescence from human arterial tissue.  In 1998 he was awarded the prestigious British Chevening Scholarship to study in the UK where he obtained the degree MBA (with distinction) in Health Planning and Management from Keele University.  In 2003, he was selected as an International Visiting fellow by the US State Department and spent 4 weeks in the US during 2004 undertaking a study tour of HIV/AIDS care centres, research institutions, etc. In 2017, he was a fellow of WIPO (World Intellectual Property Organisation) and spent 3 months at their offices in Geneva, Switzerland. He is currently Executive Manager: Strategic Research Initiatives at the South African Medical Research Council (MRC) and is responsible for establishing and maintaining institutional/consortium based research initiatives and research platforms, writing research funding proposals, grant administration, and interfacing with local and overseas funders.

Glenda
Gray

Chair

Professor Glenda Gray is the President of the Medical Research Council in South Africa, a non-Executive Director at the Perinatal HIV Research Unit (PHRU), in Soweto, South Africa, and a Professor of Paediatrics in the Faculty of Health Sciences at the University of the Witwatersrand. Her prior research has focused on: prevention of mother to child transmission studies, paediatric treatment trials, large scale HIV clinical trials (including HIV vaccine trials); TB, influenza and HPV vaccine studies in infants, children, adolescents and adults. She has been the recipient of multiple grants from the NIH, including an R21 and a U01. In 2009, she received the N’Galy Mann Lectureship award at The Conference on Retroviruses and Opportunistic Infections (CROI). Professor Gray has been the Soweto Clinical Trials Unit PI since 2010. In addition, she is the HVTN Co-PI, and Director of International/Africa Programs. Prof. Gray has been involved in HIV research in South Africa for more than a decade. She is currently leading the clinical development of South Africa’s first two HIV vaccines. She has expertise in HIV prevention in adolescents, and is the co-chair for a pivotal study investigating the efficacy of coitally dependent tenofovir gel, called FACTS 001. This multi-centered study involves multiple clinical trial sites, and is a purely South African run consortium, giving Prof. Gray the necessary experience and expertise in leading multi-centered studies. Prof. Gray serves on the WHO/UNAIDS Vaccine Advisory Board, and on the DSMB for two vaccine studies in Africa. She chairs the standing committee on health, for the Academy of Science, and represent the academy in the South African National Research Committee. As a recently inducted member of the Institute of Medicine of the National Academies, US, she served on the Global Health Committee, and the Vaccine Committee.

Jean-Pierre
Paccaud

Committee member

Dr. Jean-Pierre Paccaud is heading the business development and corporate strategy activities of GARDP since January 2017, and contributed to its inception and setup. Previously, he was heading the business development and legal teams of the Drugs for Neglected Diseases initiative (DNDi) since 2007, contributing to establish R&D partnerships with several global pharmaceutical companies as well as biotechs and academic groups. Prior to joining DNDi, Jean-Pierre founded in 2002 Athelas SA, a startup company active in the field of anti-bacterial drug discovery, which he lead until its merger with Merlion Pharmaceuticals in 2006. Trained as a molecular and cellular biologist, Jean-Pierre earned his PhD at the University of Geneva School of Medicine and completed his post-doctoral training at UC Berkeley in the lab of Prof. Randy Schekman. Before taking on entrepreneurial challenges, Jean-Pierre spent more than 18 years in academia, working in immunology, diabetes, and cell biology, and was tenured at the University of Geneva School of Medicine. He brings to GARDP a combination of business and scientific skills, entrepreneurial experience as well as negotiation and deal-making practice in the context of global public health needs.

Veronika von Messling

Committee member

Prof. Dr. Veronika von Messling, is Director-General for Life Sciences at the German Federal Ministry of Education and Research. She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany. After postdoctoral training at Mayo Clinic in Rochester, MN, she was Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore, before becoming Director of the Veterinary Division at Paul-Ehrlich-Institute, the German Federal Institute of Vaccines and Biomedicines, in Langen, Germany.

Ramanan Laxminarayan

Committee member

Ramanan Laxminarayan is founder and director of the Center for Disease Dynamics, Economics & Policy (CDDEP) in Washington, D.C., and a senior research scholar and lecturer at the Princeton Environmental Institute at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Kwazulu Natal. Laxminarayan is founder of HealthCube, which works to improve access to healthcare and diagnostics worldwide. Since 1995, Laxminarayan has worked to improve the understanding of antibiotic resistance as a problem of managing a shared global resource. His work encompasses extensive peer-reviewed research, public outreach, and direct engagement in eleven countries in Asia and Africa through the Global Antibiotic Resistance Partnership. Through his prolific research, active public outreach (including a widely viewed TED talk) and sustained policy engagement, he has played a central role in bringing the issue of drug resistance to the attention of leaders and policymakers worldwide and to the United Nations General Assembly in September 2016. Laxminarayan has served on the U.S. President’s Council of Advisors on Science and Technology’s antimicrobial resistance working group and is currently a voting member of the U.S. Presidential Advisory Council on Combating Antimicrobial Resistance. He is a series editor of the Disease Control Priorities for Developing Countries, 3rd edition. In 2003-04, he served on the National Academy of Science/Institute of Medicine Committee on the Economics of Antimalarial Drugs and subsequently helped create the Affordable Medicines Facility for malaria, a novel financing mechanism for antimalarials. In 2012, Laxminarayan created the Immunization Technical Support Unit that supports the immunization program of the Ministry of Health and Family Welfare of the Government of India and which is credited with helping rapidly improve vaccination coverage and introduction of four new vaccines. As Vice President, Research and Policy at the Public Health Foundation of India between 2011 and 2015, he led the growth of a research division to over 700 technical and research staff. Laxminarayan’s work has been covered in major media outlets including Associated Press, BBC, CNN, the Economist, LA Times, NBC, NPR, Reuters, Science, Wall Street Journal, and National Journal.

Dominique Carouge

Committee member

Mr. Dominique Carouge began his career as an external auditor at Ernst & Young in France and in the United States. Then, he joined Sanofi in 1991 where he held various financial and management positions for 29 years with increasing responsibilities in France and internationally, until he became Executive Vice-President – Business Transformation, and joined the Group’s Executive Committee in 2018. Previously, he was Chief Financial Officer for Hoechst Marion Roussel in Australia, Head of Business Planning and Reporting at Aventis Pharma in Frankfurt and Operations Controller of the Aventis Group. In 2005, he became Chief Financial Officer of the Vaccines Division, then Vice-President in charge of Strategy and Chief Financial Officer of Sanofi Pasteur. In 2011, he was appointed Vice-President, Administration and Management of Sanofi Global R&D. Then in 2016, he became Deputy Chief Financial Officer responsible for the Group’s financial operations and internal control. Mr. Dominique Carouge is a graduate of the École Supérieure de Commerce de Reims (NEOMA). He also holds a Chartered Professional Accountant (CPA) degree and a certificate of corporate governance and non-executive director from the French Institute of Directors (IFA – Science Po).

Rachel Christinat

Committee member

Gregg Alton

Committee member

Mr. Alton spent more than 20 years at Gilead Sciences, where he served in an array of leadership roles across a portfolio of responsibilities. From January 2019 until March 2019, Mr. Alton was Gilead’s interim chief executive officer. Prior to that, he was the company’s chief patient officer, responsible for Gilead’s government affairs, public affairs, patient outreach, and engagement initiatives, as well as efforts to facilitate access to its medicines around the world. During his tenure at Gilead, his wide-ranging roles included leadership of commercial operations in Europe, Asia, Latin America, and Africa, as well as global medical affairs. He also served as general counsel and chief compliance officer. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in corporate finance transactions for healthcare and information technology companies. Mr. Alton currently serves on the United States Presidential Advisory Council on HIV/AIDS, is a member of the board of directors of Novavax Inc., Brii Biosciences, Corcept Therapeutics, Enochian Biosciences, and several non-profit organizations, including The Hepatitis Fund, ETR and the Boys and Girls Clubs of Oakland. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.

Manica Balasegaram

Committee member

Dr Manica Balasegaram trained as a medical doctor at the University of Nottingham, where he started his career in internal and emergency medicine. From 2001, he worked as a doctor and researcher in Sub- Saharan Africa and Southern Asia. He also gained experience working in humanitarian emergencies and responses with Médecins Sans Frontières (MSF). In 2007, Dr. Balasegaram joined the Drugs for Neglected Diseases initiative (DNDi) as Head of Leishmaniasis Clinical Program. In 2011, he returned to MSF as Executive Director of their Access Campaign. He was appointed Executive Director of GARDP and has led the organization since 2016 through its incubation to an independent legal entity, during which time GARDP launched four programmes and built a skilled and dedicated team with expertise from a range of sectors and backgrounds. Dr Balasegaram has significant experience in organizational governance and is currently a board member of the Medicines Patent Pool as well as of FIND’s Scientific Advisory Committee. He has also previously served as a Board Member and Secretary of Médecins Sans Frontières (Switzerland). His experience spans clinical and public health practice in infectious diseases to international work on health policy & access to medicines. He has served on numerous technical and health policy panels, including notably as a Member of the Expert Advisory Group of the UN High Level Panel on Access to Medicines (2015-16) and a Member of the World Health Organization Scientific Advisory Group for the Blueprint on Research & Development Preparedness (2015 and ongoing). With over 20 years' experience in Global Health, Dr Balasegaram has a proven track record in partnership building, resource mobilization, public and private sector stakeholder management and governance.

Seamus O’Brien

Committee member

Seamus O’Brien joined GARDP as R&D Director in July 2018. Prior to joining as GARDP’s R&D Director, Seamus O’Brien was most recently responsible for building and leading R&D collaborations, partnerships, and networks to address leading pharmaceutical companies’ (Pfizer and previously AstraZeneca) commitment to develop treatment options for antibiotic resistant infections. In particular he played a leading role in establishing novel partnerships with the US government’s Biomedical Advanced Research and Development Authority as principal investigator for an antibiotic portfolio agreement and with the Innovative Medicines Initiative (IMI) New Drugs 4 Bad Bugs programme within Europe as leader of the COMBACTE-CARE consortium addressing carbapenem resistance. He has also represented both AstraZeneca and Pfizer Essential Health on the Infection Control Strategic Governance Group for IMI. Before joining Pfizer, Seamus worked for 10 years for AstraZeneca, initially leading physicians and scientists in the clinical development of oncology and infection products. He played a leading role in building a standalone infection unit to address AstraZeneca’s commitment to developing antibiotics for unmet medical need. He was responsible for bringing a novel antibiotic combination candidate through phase I to phase II and designing a streamlined clinical development programme aligned with emerging regulatory guidance. Seamus brings with him a wealth of experience in pharmaceutical drug development from antibiotic to vaccine clinical development, across a range of sectors, to leading medical affairs support for a number of product launches. He has a PhD in Mycobacterium tuberculosis infection and host immunity from the Wellcome Trust/University of Leicester and first degree in Microbiology from Trinity College Dublin.

Ramanan Laxminarayan

Chair

Ramanan Laxminarayan is founder and director of the Center for Disease Dynamics, Economics & Policy (CDDEP) in Washington, D.C., and a senior research scholar and lecturer at the Princeton Environmental Institute at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Kwazulu Natal. Laxminarayan is founder of HealthCube, which works to improve access to healthcare and diagnostics worldwide. Since 1995, Laxminarayan has worked to improve the understanding of antibiotic resistance as a problem of managing a shared global resource. His work encompasses extensive peer-reviewed research, public outreach, and direct engagement in eleven countries in Asia and Africa through the Global Antibiotic Resistance Partnership. Through his prolific research, active public outreach (including a widely viewed TED talk) and sustained policy engagement, he has played a central role in bringing the issue of drug resistance to the attention of leaders and policymakers worldwide and to the United Nations General Assembly in September 2016. Laxminarayan has served on the U.S. President’s Council of Advisors on Science and Technology’s antimicrobial resistance working group and is currently a voting member of the U.S. Presidential Advisory Council on Combating Antimicrobial Resistance. He is a series editor of the Disease Control Priorities for Developing Countries, 3rd edition. In 2003-04, he served on the National Academy of Science/Institute of Medicine Committee on the Economics of Antimalarial Drugs and subsequently helped create the Affordable Medicines Facility for malaria, a novel financing mechanism for antimalarials. In 2012, Laxminarayan created the Immunization Technical Support Unit that supports the immunization program of the Ministry of Health and Family Welfare of the Government of India and which is credited with helping rapidly improve vaccination coverage and introduction of four new vaccines. As Vice President, Research and Policy at the Public Health Foundation of India between 2011 and 2015, he led the growth of a research division to over 700 technical and research staff. Laxminarayan’s work has been covered in major media outlets including Associated Press, BBC, CNN, the Economist, LA Times, NBC, NPR, Reuters, Science, Wall Street Journal, and National Journal.

Hiroki
Nakatani

Committee member

In recent years, Dr. Hiroki Nakatani has held academic positions in Japan as Project Professor at the Global Research Institute of Keio University, and Invited Professor at Osaka University Post Graduate School of Medicine. He also serves in various national and international organizations as Chair, Board of Directors, Global Health Innovative Technology Fund (GHIT Fund); Senior-Advisor, Economic Research Institute for ASEAN and East Asia (ERIA; Director, Hub on Population Ageing, Association of Pacific Rim Universities (APRU); Member, Board of Directors, National Center for Global Health and Medicine; and Director, Human Resource Strategy Center for Global Health. He is a veteran public health specialist for over 40 years, who started his career at the Ministry of Health, Labour and Welfare in Japan. He worked extensively in the area of health policy, public health, international health, and health science and technology. His national career includes serving as Director-General of Health and Welfare Services in Hiroshima Prefecture, where he was in charge of integration of health and welfare services in preparation for the arrival of a rapidly ageing society. With regards to international career, he served the WHO Headquarters twice. From April 1988 to March 1993, he was Policy Analysist in the Department of Human Resource for Health. From March 2007 to May 2015, he served as Assistant Director-General of WHO, leading the largest technical cluster of HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases. During his tenure, the morbidity and mortality of these three major infections showed trends of decline, and a few tropical diseases were on track towards elimination and even eradication (dracunculiasis or guinea worm disease). Dr. Nakatani received his MD from Keio University School of Medicine, MHPEd from the University of New South Wales, and PhD from Keio University.

John-Arne Røttingen

Committee member

John-Arne Røttingen is Ambassador for Global Health at the Ministry of Foreign Affairs, Norway. He is Adjunct Scientific Director at the Norwegian Institute of Public Health and Visiting Fellow of Practice at Blavatnik School of Government, Oxford University. He was the founding CEO of CEPI – Coalition for Epidemic Preparedness Innovations; and has been the Chief Executive of the Research Council of Norway; Executive Director of Infection Control and Environmental Health at the Norwegian Institute of Public Health; founding Chief Executive of the Norwegian Knowledge Centre for the Health Services; Professor of Health Policy at the Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo; and Adjunct Professor at the Department of Global Health and Population, Harvard T.H. Chan School of Public Health. He is member of the Norwegian Academy of Science and Letters and the US National Academy of Medicine. He received his MD and PhD from the University of Oslo, an MSc from Oxford University and an MPA from Harvard University.

Stanislas
Zuin

Committee member

Stanislas ZUIN is a certified internal auditor (CIA) and a certified fraud examiner (CFE). He holds master degrees in both economics and economic crime investigation, as well as a certificate in development studies. Throughout his career he has worked as a private banking financial analyst, a corporate finance executive, and CFO for both privately-owned and listed industrial companies. He later founded his own consulting firm in economic crime investigation, before being elected from 2006 to 2018 as magistrate at the Court of auditors of Geneva, Switzerland. As magistrate he has managed numerous compliance and performance audits as well as fraud investigations and evaluation of public policies. He has served four years as the President of the Court and is a frequent lecturer at Universities in the fields of public finance, investigation and audit. He currently leads its own consultancy company in the field of audit and governance, together with responsibilities as Board Vice President of Geneva International Airport, in charge of Audit & Finance committee, and as Board Member of the Geneva federation for cooperation and development (FGC).

Stanislas Zuin

Chair

Stanislas ZUIN is a certified internal auditor (CIA) and a certified fraud examiner (CFE). He holds master degrees in both economics and economic crime investigation, as well as a certificate in development studies. Throughout his career he has worked as a private banking financial analyst, a corporate finance executive, and CFO for both privately-owned and listed industrial companies. He later founded his own consulting firm in economic crime investigation, before being elected from 2006 to 2018 as magistrate at the Court of auditors of Geneva, Switzerland. As magistrate he has managed numerous compliance and performance audits as well as fraud investigations and evaluation of public policies. He has served four years as the President of the Court and is a frequent lecturer at Universities in the fields of public finance, investigation and audit. He currently leads its own consultancy company in the field of audit and governance, together with responsibilities as Board Vice President of Geneva International Airport, in charge of Audit & Finance committee, and as Board Member of the Geneva federation for cooperation and development (FGC).

Dominique Carouge

Committee member

Mr. Dominique Carouge began his career as an external auditor at Ernst & Young in France and in the United States. Then, he joined Sanofi in 1991 where he held various financial and management positions for 29 years with increasing responsibilities in France and internationally, until he became Executive Vice-President – Business Transformation, and joined the Group’s Executive Committee in 2018. Previously, he was Chief Financial Officer for Hoechst Marion Roussel in Australia, Head of Business Planning and Reporting at Aventis Pharma in Frankfurt and Operations Controller of the Aventis Group. In 2005, he became Chief Financial Officer of the Vaccines Division, then Vice-President in charge of Strategy and Chief Financial Officer of Sanofi Pasteur. In 2011, he was appointed Vice-President, Administration and Management of Sanofi Global R&D. Then in 2016, he became Deputy Chief Financial Officer responsible for the Group’s financial operations and internal control. Mr. Dominique Carouge is a graduate of the École Supérieure de Commerce de Reims (NEOMA). He also holds a Chartered Professional Accountant (CPA) degree and a certificate of corporate governance and non-executive director from the French Institute of Directors (IFA – Science Po).

Bernard Pécoul

Committee member

Dr Bernard Pécoul has led the Drugs for Neglected Diseases initiative (DNDi) since its foundation in 2003. Under his guidance, DNDi – a not-for-profit research and development organization – with hundreds of public and private partners, has delivered seven new treatments for the most neglected diseases (leishmaniasis, sleeping sickness, and Chagas disease) and for malaria. It has developed a robust portfolio of projects spanning from discovery to implementation for these diseases as well as filaria, paediatric HIV, mycetoma, and hepatits C. As part of DNDi’s dynamic portfolio approach, Dr Pécoul is also leading the incubation of a product development partnership to address R&D for new antibiotic treatments. DNDi aims to deliver a total of 16 to 18 new treatments for neglected patients by 2023, with a total of EUR 650 million, spanning 10 disease areas. The initiative, through its R&D work, also builds capacity in disease endemic countries through research platforms and technology transfers and advocates for greater public leadership to sustainably address the health needs of neglected patients. Prior to DNDi, Dr Pécoul was Director of the Médecins Sans Frontières (MSF) Campaign for Access to Essential Medicines from 1998 to 2003, a position he took on after that of Executive Director of MSF-France. While working with MSF, Dr Pécoul carried out field missions in Africa, Latin America, and Asia. In 1988, he co-founded Epicentre, an MSF-affiliated NGO specialized in epidemiology. After obtaining his medical degree at the University of Clermont-Ferrand, France, Dr Pécoul earned a master’s degree in public health at Tulane University, USA. In 2012, he was awarded an honorary Doctor of Laws Degree by the University of Dundee, UK. Bernard Pécoul is member of the Joint Coordination Board of the Special Programme for Tropical Disease Research (WHO/TDR) and a former board member of UNITAID’s Medicines Patent Pool.

Tal Schibler

Committee member